A new Johns Hopkins analysis of 205,896 branded medication fills offers the first national look inside the prior authorization process — tracking how long patients wait, who gets approved, and who bears the cost.
A study of Medicare Part D beneficiaries found that nearly 1 in 7 new users of diabetes-indicated GLP-1 medications in early 2023 had no evidence of diabetes, up from 1.3% in 2019. The findings highlight the budgetary implications of off-label GLP-1 prescribing as policymakers consider expanding Medicare coverage for weight management.
HBHI invited a panel of three guests to discuss this issue: Katey Bey, Global Head, Total Rewards, Sedgwick; Gregory Daniel, PhD, MPH, Vice President & Head of Global Public Policy, Eli Lilly and Company; and Shantanu Nundy, MD, EVP Care Delivery and Chief Health Officer, Accolade.
HBHI Work-in-Progress (WIP) is a forum for supporting early-stage research on HBHI topics as a Hopkins community of scholars from multiple disciplines across Carey, Bloomberg, Medicine, Nursing, Krieger, and Engineering.
Johns Hopkins University just announced its 35 Discovery Award winners for 2023. Hopkins Business of Health Initiative is excited to announce that two of these projects will be awarded additional seed grant funding by HBHI.
